Methotrexate for ectopic pregnancy: when and how.

Area of Science:

• Reproductive Medicine
• Gynecology
• Pharmacology

Background:

• Ectopic pregnancy is a leading cause of first-trimester maternal mortality.
• Advances in beta-hCG monitoring and transvaginal ultrasound enable earlier diagnosis and conservative management.
• Systemic methotrexate (MTX) presents a minimally invasive, effective alternative for ectopic pregnancy treatment.

Purpose of the Study:

• To review the efficacy and application of methotrexate (MTX) in managing ectopic pregnancies.
• To analyze current trends and evidence supporting conservative treatment options for ectopic pregnancy.

Main Methods:

• Systematic literature search of high-impact journals (2003-2013) using databases like MEDLINE, Cochrane Library, DARE, PROSPERO.
• Inclusion of studies on ectopic pregnancy and methotrexate, focusing on evidence-based recommendations.
• Classification of 32 selected studies based on Oxford Centre for Evidence-Based Medicine criteria.

Main Results:

• A discernible trend towards conservative management of ectopic pregnancies is evident in recent literature.
• Single-dose methotrexate protocols are well-established and supported by a significant body of research.
• Expectant management protocols require further investigation for definitive conclusions.

Conclusions:

• Methotrexate is most effective for ectopic pregnancies with low beta-hCG titers and small gestational sac diameters, though standardization is lacking.
• Treatment decisions are influenced by the medical team's experience and the patient's reproductive aspirations.
• MTX provides a viable, non-invasive option for ectopic pregnancy management.